文献速递免疫规划传染病防控与疫情报告

羊驼接种裂谷热病毒MP-12疫苗的安全性、免疫原性与致病性

Vaccination of alpacas against Rift Valley fever virus: Safety, immunogenicity and pathogenicity of MP-12 vaccine.
PubMed 文献 · Vaccine · 2016-12-21

本研究以三只羊驼作为单峰骆驼模型,评估MP-12疫苗的安全性与免疫原性,分别在感染后3天和31天实施安乐死。结果显示疫苗耐受良好,无显著不良反应,可诱导高滴度中和抗体;但接种后3天血清和肝脏中可检出病毒,并见轻度多灶性坏死性肝炎,提示MP-12仍有残余致病性,需进一步研究。

要点

  • MP-12疫苗接种羊驼后耐受良好,未观察到显著不良反应。
  • 疫苗可诱导高滴度的中和抗体及针对不同病毒抗原的抗体。
  • 接种后3天可检出病毒并见轻度多灶性坏死性肝炎,提示残余致病性。

核心结论

  • MP-12是有前景的疫苗候选,但仍具有残余致病性,需要进一步研究。

研究设计与样本

  • 研究使用三只羊驼作为单峰骆驼的模型动物,评估MP-12疫苗的安全性、免疫原性和致病性,动物分别在感染后3天和31天实施安乐死以比较急性和亚急性效应。

主要发现

  • 临床监测、肝酶分析和血液学参数表明疫苗耐受良好,未观察到显著不良反应。
  • 血清学参数分析显示疫苗具有免疫原性,可诱导高滴度中和抗体及针对不同病毒抗原的抗体。
  • 在感染后3天安乐死的羊驼血清和肝脏中检测到裂谷热病毒,而在31天时未检出病毒。
  • 免疫组化在肝细胞中检测到多种裂谷热病毒抗原,并观察到轻度多灶性坏死性肝炎,确认病毒复制。

关键数值与推荐

  • 原文未报告关键数值与推荐。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • MP-12仍有残余致病性,需要进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rift Valley fever (RVF) is an emerging zoonosis of major public health concern in Africa and Arabia. Previous outbreaks attributed camelids a significant role in the epidemiology of Rift Valley fever virus (RVFV), making them an important target species for vaccination. Using three alpacas as model-organisms for dromedary camels, the safety, immunogenicity and pathogenicity of the MP-12 vaccine were evaluated in this study. To compare both acute and subacute effects, animals were euthanized at 3 and 31days post infection (dpi). Clinical monitoring, analysis of liver enzymes and hematological parameters demonstrated the tolerability of the vaccine, as no significant adverse effects were observed. Comprehensive analysis of serological parameters illustrated the immunogenicity of the vaccine, eliciting high neutralizing antibody titers and antibodies targeting different viral antigens. RVFV was detected in serum and liver of the alpaca euthanized 3dpi, whereas no virus was detectable at 31dpi. Viral replication was confirmed by detection of various RVFV-antigens in hepatocytes by immunohistochemistry and the presence of mild multifocal necrotizing hepatitis. In conclusion, results indicate that MP-12 is a promising vaccine candidate but still has a residual pathogenicity, which requires further investigation.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Rissmann M, Ulrich R, Schröder C, et al. Vaccination of alpacas against Rift Valley fever virus: Safety, immunogenicity and pathogenicity of MP-12 vaccine. Vaccine. 2016. PMID: 28012779. doi:10.1016/j.vaccine.2016.12.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。